Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a meta-analysis

Int J Cardiol. 2011 Sep 15;151(3):348-53. doi: 10.1016/j.ijcard.2011.05.045. Epub 2011 Jun 1.


Background: Although the pleiotropic effects of statins are postulated to be renoprotective, clinical studies have demonstrated conflicting results. We undertook a meta-analysis of published trials to evaluate the impact of statin therapy on the incidence of contrast-induced nephropathy (CIN) in patients undergoing coronary angiography.

Methods: We searched MEDLINE and EMBASE databases through December 2010 for articles evaluating the effect of statins on the incidence of CIN in patients undergoing coronary angiography. Odds ratios (OR) with 95% confidence intervals (CI) were calculated using random effects modeling.

Results: Three randomized controlled trials involving 770 patients (330 in the statin group and 340 in the control group) and 7 non-randomized studies involving 31,959 patients (11,936 statin-pretreated and 20,023 statin-naïve). The definition of CIN varied somewhat among the studies. Based on the pooled estimate across the 3 randomized controlled trials, statin therapy did not significantly reduce the incidence of CIN compared to control (OR=0.76, 95% CI: 0.41-1.41, p=0.39). No significant heterogeneity was found in the randomized studies (I(2)=0%, p=0.48). The pooled analysis of the non-randomized studies showed a marginally significant benefit associated with statin therapy (OR=0.60, 95% CI: 0.36-1.00, p=0.05). There was significant heterogeneity among the non-randomized studies (I(2)=88%, p<0.00001).

Conclusions: Our meta-analysis suggests that statin therapy might be associated with a significant reduction in the incidence of CIN in patients undergoing coronary angiography. Further studies are warranted to clarify this issue.

Publication types

  • Meta-Analysis

MeSH terms

  • Contrast Media / adverse effects*
  • Coronary Angiography / adverse effects*
  • Glomerulonephritis, Membranous / chemically induced*
  • Glomerulonephritis, Membranous / drug therapy*
  • Glomerulonephritis, Membranous / enzymology
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Randomized Controlled Trials as Topic / methods


  • Contrast Media
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors